Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
As non-EU manufacturers prepare for the EU AI Act, many are exploring whether their existing GDPR Article 27 Representative can also serve as their Authorised Representative for AI systems. While cons...
When budgeting for an EU Authorized Representative (AR) under the AI Act, how can non-EU manufacturers accurately forecast costs when service fees are not standardized? The pricing for an AR can vary ...
Beyond the basic requirement that foreign medical device establishments must designate a U.S. Agent, what are the detailed responsibilities and critical qualifications that define this role? FDA's reg...
When budgeting for European Union market compliance for 2026, many medical device manufacturers consider outsourcing the Person Responsible for Regulatory Compliance (PRRC) role. While this 'as a Serv...
For non-EU based medical device and SaMD companies preparing their compliance strategies for 2026, what is a comprehensive framework for selecting a GDPR Article 27 Representative that moves beyond a ...
As the European Union's regulatory landscape grows more complex with frameworks like the Medical Device Regulation (MDR) and broad-reaching initiatives such as the Carbon Border Adjustment Mechanism (...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), what are the precise operational and legal requirements for an entity serving as an FDA U.S. Agent for a foreign cosme...
When budgeting for EU MDR compliance into 2026, how can medical device manufacturers forecast the cost of engaging a "Person Responsible for Regulatory Compliance (PRRC) as a Service"? While specific ...
For non-EU manufacturers planning their European market strategy for 2026, what are the key service and portfolio factors that determine the cost of appointing a REACH Only Representative (OR)? Rather...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must designate a U.S. Agent to serve as a point of contact for the FDA. While this is a mandatory requirement f...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities are required to designate a U.S. Agent for FDA registration and as a point of contact. This new mandate raises ...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must designate a U.S. Agent to facilitate communication with the FDA. While there is no standard, fixed fee for...
When evaluating 'Person Responsible for Regulatory Compliance (PRRC) as a Service' providers, how can manufacturers move beyond a simple comparison of annual fees to conduct a comprehensive cost-value...
When a medical device manufacturer, particularly a small or non-EU based entity, decides to outsource the role of the Person Responsible for Regulatory Compliance (PRRC) as permitted under the EU MDR,...
When a medical device manufacturer decides to outsource the Person Responsible for Regulatory Compliance (PRRC) role required under European regulations, what specific, practical framework can be used...
As global regulations and scientific understanding of certain chemical substances evolve, how should medical device sponsors approach FDA premarket submissions for devices containing materials that fa...
With increasing regulatory scrutiny on per- and polyfluoroalkyl substances (PFAS) under REACH, and with significant ECHA developments anticipated around 2026, non-EU manufacturers face a critical chal...
For non-EEA manufacturers preparing for the forthcoming EU REACH restrictions on Per- and Polyfluoroalkyl Substances (PFAS), selecting a qualified Only Representative (OR) is a crucial step, particula...
For non-EU medical device manufacturers, how might the announced 2026 changes to France's VAT and import agent requirements affect logistical operations and overall EU market strategy? While CE markin...
For sponsors of a novel Software as a Medical Device (SaMD) that appears to lack a clear predicate device, what is the systematic process for determining the appropriate US regulatory pathway, specifi...